{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:O00400",
      "entity_text" : "AT1",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:65999",
      "entity_text" : "telmisartan",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "In September 2008, treatment with the AT1 blocker telmisartan (20 mg/day) was started due to borderline hypertension.",
  "reading_complete" : "2020-08-02T15:13:48Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-02T15:11:33Z",
  "trigger" : "blocker",
  "evidence" : [ "AT1 blocker telmisartan" ],
  "pmc_id" : "4192324",
  "score" : 0
}